Who are Paclitaxel for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo plus Docetaxel, Docetaxel (DOC), Paclitaxel injection, Docetaxel or albumin paclitaxel, Paclitaxel, Epirubicin, Cabazitaxel (XRP6258).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Paclitaxel for Injection — Competitive Intelligence Brief

Paclitaxel for Injection (Paclitaxel for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin; microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel for Injection (Paclitaxel for Injection) — Bio-Thera Solutions. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel for Injection TARGET	Paclitaxel for Injection	Bio-Thera Solutions	phase 3	Taxane; microtubule stabilizer	β-tubulin; microtubules
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
Paclitaxel, Epirubicin	Paclitaxel, Epirubicin	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (taxane + anthracycline)	Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

Sanofi · 2 drugs in this class
Aravive, Inc. · 1 drug in this class
Athenex, Inc. · 1 drug in this class
Barts & The London NHS Trust · 1 drug in this class
BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Dai, Guanghai · 1 drug in this class
Fujian Medical University · 1 drug in this class
Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-for-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab